Core Viewpoint - Silvercorp (SVM) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ended March 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The earnings report is expected to be released on May 22, 2025, with a consensus estimate of $0.09 per share, reflecting a year-over-year increase of 350% [3]. - Revenues are projected to reach $75.1 million, which is a 76% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 16.67% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [7][8]. - Silvercorp currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11]. Historical Performance - In the last reported quarter, Silvercorp met the expected earnings of $0.10 per share, resulting in no surprise [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Conclusion - While Silvercorp does not appear to be a compelling earnings-beat candidate, investors should consider other factors when making decisions regarding the stock ahead of its earnings release [16].

The market expects Home Depot (HD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended April 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...

The market expects Toll Brothers (TOL) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended April 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

Core Viewpoint - Kratos Defense & Security Solutions, Inc. reported a mixed performance in its first-quarter 2025 results, with adjusted earnings exceeding expectations but a decline in share price following the announcement [1][8]. Financial Performance - Adjusted earnings for Q1 2025 were 12 cents per share, a 9.1% increase from 11 cents in the same quarter last year, and surpassed the Zacks Consensus Estimate of 9 cents by 33.3% [1]. - Total revenues reached $302.6 million, exceeding the Zacks Consensus Estimate of $292 million by 3.6% and reflecting a 9.2% increase from $277.2 million in the prior-year quarter [2]. - Operating income was reported at $6.6 million, down from $7 million in the year-ago quarter [3]. Segment Performance - Unmanned Systems segment saw net revenues improve by 6.2% year over year to $63.1 million, driven by increased target drone sales [5]. - Kratos Government Solutions segment reported a 10% increase in net revenues to $239.5 million, attributed to growth in C5ISR, Defense Rocket Support, and Microwave Products businesses [5]. Operational Metrics - The company reported a consolidated book-to-bill ratio of 1.2-1.0, with bookings totaling $365.6 million and a total backlog of $1.51 billion, up from $1.45 billion at the end of 2024 [4]. - Selling, general and administrative expenses increased by 3.8% year over year, while research and development expenses rose by 4.2% [3]. Cash Flow and Debt - As of March 30, 2025, cash and cash equivalents totaled $263.7 million, down from $329.3 million as of December 29, 2024 [6]. - Long-term debt decreased to $172.2 million from $174.6 million as of December 29, 2024 [6]. - The net cash outflow from operating activities was $29.2 million during the first three months of 2025, compared to a net cash inflow of $0.7 million in the previous year [6]. Guidance - For Q2 2025, the company projects revenues in the range of $300-$310 million, while the full-year 2025 revenue guidance remains at $1.26-$1.29 billion [8]. - Operating cash flows are expected to be between $50-$60 million, with free cash outflow projected at $75-$85 million for 2025 [9].

For the quarter ended March 2025, Paramount Global-B (PARA) reported revenue of $7.19 billion, down 6.4% over the same period last year. EPS came in at $0.29, compared to $0.62 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $7.08 billion, representing a surprise of +1.53%. The company delivered an EPS surprise of +7.41%, with the consensus EPS estimate being $0.27.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Core Insights - Mirum Pharmaceuticals reported a narrower loss of 30 cents per share in Q1 2025, compared to a loss of 54 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 39 cents [1][2] - The company's revenues for Q1 2025 reached $111.6 million, reflecting a year-over-year increase of nearly 62%, surpassing the Zacks Consensus Estimate of $98 million [2][3] Financial Performance - Livmarli's net product sales were $73.2 million in Q1 2025, marking a 71% increase year over year, with U.S. sales at $49.5 million and ex-U.S. sales at $23.7 million [6] - Net product sales from bile acid products, including Cholbam and Ctexli, totaled $38.4 million in Q1 2025, up 47% year over year [7] - Research and development expenses rose by 42.8% year over year to $46 million, while selling, general, and administrative expenses increased by 26.5% to $57.7 million [7][8] Guidance and Future Outlook - Mirum raised its full-year revenue guidance for 2025 to a range of $435-$450 million, up from the previous estimate of $420-$435 million, due to strong demand for its commercial products [9] - The company is evaluating Livmarli in a phase III study for treating pruritus in rare cholestatic conditions, with enrollment expected to complete in 2026 [10] Recent Developments - The FDA approved a new tablet formulation of Livmarli for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis [10] - Ctexli tablets received FDA approval for treating adults with cerebrotendinous xanthomatosis, becoming the first approved treatment for this condition [11] - Mirum's lead pipeline candidate, volixibat, is in two phase IIb studies for primary biliary cholangitis and primary sclerosing cholangitis, with enrollment expected to complete in 2026 [11][12]

Core Viewpoint - Acadia Healthcare Company, Inc. (ACHC) is expected to report first-quarter 2025 results on May 12, with earnings estimated at 42 cents per share and revenues at $770.5 million, indicating a year-over-year earnings decline of 50% but a slight revenue growth of 0.3% [1][2]. Financial Estimates - First-quarter earnings estimates have declined by 8 cents per share over the past 60 days, reflecting a significant year-over-year decrease [2]. - For the full year 2025, the revenue estimate for Acadia Healthcare is $3.33 billion, representing a year-over-year increase of 5.7%, while the EPS estimate is $2.76, indicating a decline of 16.4% year-over-year [2]. Recent Performance - Acadia Healthcare has beaten earnings estimates in three of the last four quarters, with an average surprise of negative 0.4% [3]. Earnings Prediction Model - The current model does not predict an earnings beat for Acadia Healthcare, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [4]. Revenue Drivers - Revenue per patient day is estimated to rise by 2% year-over-year, and revenues from Residential Treatment Centers are expected to increase by 9.7% from $85.6 million a year ago [6]. - U.S. same-facility admissions are projected to show a marginal increase, while revenues from Specialty Treatment Facilities are expected to rise by 0.1% from $143.8 million [7]. Expense Concerns - Rising expenses are anticipated to impact profit levels, with total expenses expected to increase by more than 11% due to higher salaries, wages, benefits, and other operating costs [8]. - Supply costs are also expected to rise due to increased utilization [8]. Revenue Declines in Specific Areas - Revenues from Acute Inpatient Psychiatric Facilities are projected to decrease by 1.3% from $401.1 million, and same-facility patient days are expected to decline by 1.1% year-over-year [9]. - Comprehensive Treatment Centers' revenues are estimated to fall by 0.5% from $132.2 million [9].

Core Viewpoint - Wall Street anticipates a year-over-year decline in Walmart's earnings despite an increase in revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - Walmart is expected to report quarterly earnings of $0.58 per share, reflecting a year-over-year decrease of 3.3%, while revenues are projected to be $165.56 billion, an increase of 2.5% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.76% over the last 30 days, indicating a bearish sentiment among analysts regarding Walmart's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Walmart is lower than the consensus estimate, resulting in an Earnings ESP of -1.69%, which complicates the prediction of an earnings beat [10][11]. Historical Performance - In the last reported quarter, Walmart exceeded earnings expectations with a surprise of +1.54%, having beaten consensus EPS estimates in the last four quarters [12][13]. Market Reaction Factors - An earnings beat or miss alone may not dictate stock movement, as other factors can influence investor sentiment and stock performance [14][16].

Core Viewpoint - The market anticipates Gambling.com Group Limited (GAMB) to report a year-over-year increase in earnings driven by higher revenues for the quarter ending March 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected on May 15, 2025, with a consensus EPS estimate of $0.25, reflecting a 25% year-over-year increase, and revenues projected at $40.38 million, a 38.2% increase from the previous year [3][2]. - A positive earnings surprise could lead to a stock price increase, while a miss may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.61% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -25%, complicating predictions for an earnings beat [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likelihood of actual earnings deviating from consensus estimates, with positive readings being more predictive of earnings beats [5][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - Gambling.com has a history of beating consensus EPS estimates, having done so in the last four quarters, including a 40% surprise in the last reported quarter [12][13]. Conclusion - Despite the historical performance, Gambling.com does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors before making investment decisions [16].

Core Viewpoint - The market anticipates a year-over-year decline in Deere's earnings due to lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Deere is expected to report quarterly earnings of $5.68 per share, reflecting a year-over-year decrease of 33.4% [3]. - Revenue projections stand at $10.65 billion, down 21.8% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 1.85% over the last 30 days, indicating a bearish sentiment among analysts [4]. - The Most Accurate Estimate for Deere is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.24% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive reading is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [8]. - However, a negative Earnings ESP does not necessarily indicate an earnings miss, making predictions less reliable [9]. Historical Performance - In the last reported quarter, Deere exceeded expectations with earnings of $3.19 per share against an estimate of $3.13, resulting in a surprise of +1.92% [12]. - Over the past four quarters, Deere has consistently beaten consensus EPS estimates [13]. Conclusion - Despite the potential for an earnings miss, betting on stocks expected to beat earnings can improve success odds, highlighting the importance of monitoring Earnings ESP and Zacks Rank [15]. - Currently, Deere does not appear to be a strong candidate for an earnings beat, suggesting investors should consider other factors before making decisions [16].